• LAST PRICE
    40.9100
  • TODAY'S CHANGE (%)
    Trending Down-1.1200 (-2.6648%)
  • Bid / Lots
    38.2300/ 1
  • Ask / Lots
    41.7000/ 1
  • Open / Previous Close
    41.1000 / 42.0300
  • Day Range
    Low 40.1900
    High 41.1800
  • 52 Week Range
    Low 3.6900
    High 53.8200
  • Volume
    384,141
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 42.03
TimeVolumeSLNO
09:32 ET322541.1
09:56 ET70041.12
09:57 ET21641.1
10:10 ET10040.91
10:12 ET60041.025
10:14 ET10041.15
10:19 ET110040.91
10:26 ET10040.81
10:32 ET25240.84
10:33 ET20041.09
10:39 ET10040.92
10:42 ET11141.01
10:48 ET40041.055
10:50 ET10041.055
10:51 ET10041.01
10:55 ET20041.025
10:57 ET250040.57
11:00 ET111540.66
11:02 ET10040.685
11:04 ET10040.64
11:08 ET172140.8
11:09 ET60040.92
11:11 ET131940.94
11:13 ET908740.92
11:15 ET50040.9
11:18 ET10040.91
11:20 ET162840.9
11:22 ET160040.895
11:27 ET20040.865
11:29 ET10040.865
11:33 ET140040.905
11:36 ET10040.88
11:38 ET10040.99
11:40 ET20040.98
11:44 ET10041
11:47 ET292040.99
11:49 ET91740.985
11:51 ET10040.95
11:54 ET10040.95
11:58 ET20040.945
12:00 ET20040.945
12:02 ET90040.945
12:03 ET190040.81
12:05 ET102240.71
12:09 ET65540.65
12:16 ET10040.64
12:20 ET20040.72
12:21 ET10040.69
12:23 ET150040.58
12:25 ET20040.6
12:27 ET10040.58
12:32 ET10040.6
12:34 ET10040.56
12:38 ET52640.67
12:39 ET10040.65
12:41 ET10040.74
12:43 ET10040.62
12:45 ET22340.6454
12:50 ET10040.6
12:54 ET10040.665
12:56 ET80040.52
01:01 ET20040.49
01:06 ET30040.49
01:08 ET60040.41
01:10 ET10040.37
01:12 ET60040.31
01:14 ET10040.24
01:15 ET20040.24
01:17 ET30040.23
01:19 ET200040.44
01:24 ET10040.465
01:26 ET460040.39
01:32 ET30040.4164
01:35 ET40040.35
01:42 ET20040.41
01:44 ET360040.75
01:46 ET129940.565
01:48 ET165040.49
01:50 ET20040.52
01:53 ET20040.52
01:57 ET54440.52
02:00 ET10040.5
02:04 ET40040.35
02:06 ET30040.3
02:11 ET40040.32
02:13 ET380740.49
02:15 ET184540.545
02:18 ET10040.46
02:20 ET10040.64
02:24 ET10040.51
02:27 ET20040.5
02:29 ET10040.555
02:33 ET10040.48
02:36 ET69740.48
02:38 ET51840.43
02:40 ET70040.495
02:45 ET10040.43
02:47 ET10040.485
02:49 ET140040.46
02:51 ET20040.41
02:56 ET170040.49
02:58 ET10040.47
03:00 ET20040.56
03:02 ET10040.56
03:03 ET20040.56
03:05 ET40040.45
03:07 ET160040.46
03:09 ET260040.66
03:12 ET40040.68
03:14 ET20040.6
03:16 ET10040.71
03:18 ET20040.7
03:20 ET90040.56
03:21 ET251040.8
03:23 ET60040.91
03:25 ET50040.9
03:27 ET10040.91
03:32 ET75840.83
03:36 ET10040.83
03:38 ET20040.78
03:39 ET20040.8
03:41 ET100440.92
03:43 ET140040.855
03:45 ET60040.86
03:48 ET208240.83
03:50 ET150440.85
03:52 ET171840.93
03:54 ET121141.04
03:56 ET605841.105
03:57 ET151141.035
03:59 ET1089540.91
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLNO
Soleno Therapeutics Inc
1.5B
-15.3x
---
United StatesAKRO
Akero Therapeutics Inc
1.5B
-6.7x
---
United StatesKROS
Keros Therapeutics Inc
1.5B
-8.2x
---
United StatesBLTE
Belite Bio Inc
1.4B
-38.7x
---
United StatesKURA
Kura Oncology Inc
1.5B
-9.2x
---
United StatesNMRA
Neumora Therapeutics Inc
1.6B
-6.6x
---
As of 2024-07-05

Company Information

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Contact Information

Headquarters
203 Redwood Shores Parkway, Suite 500REDWOOD CITY, CA, United States 94065
Phone
650-213-8444
Fax
302-655-5049

Executives

Independent Chairman of the Board
Ernest Mario
President, Chief Executive Officer, Chief Operating Officer, Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Senior Vice President - Clinical Development
Michael Huang
Senior Vice President - Clinical Operations
Kristen Yen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$0.00
Shares Outstanding
34.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.39
EPS
$-2.68
Book Value
$4.97
P/E Ratio
-15.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.